Besides their RCTs on patients with MS, Vermersch et al. also explored the effects of masitinib using a myelin oligodendrocyte glycoprotein murine model, and found a significant reduction in disease, as assessed by the mean clinical score [8]. This evidence concerns the gene MOG and myeloid sarcoma.